Plain-English translation of NCT07089121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new cell-based therapy designed to treat four serious autoimmune diseases in children and young adults: childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. Researchers want to find out if this treatment is safe, well-tolerated, and effective in reducing symptoms and disease activity in these young patients.
These four autoimmune diseases can cause serious damage to organs and muscles in children and teenagers, and current treatments don't work well enough for everyone. This trial explores whether a new cell-based approach might offer a better option for young people living with these conditions.
You likely qualify if…
You likely don't qualify if…
The study has two parts. In Part 1, you will receive six infusions of the medication over several weeks, with the dose gradually increasing to find the safest level. In Part 2, you will receive weekly infusions of the medication at the best dose found in Part 1 for 6 weeks. You will have regular visits with the research team to have blood tests and check how you're responding to treatment.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States